All Roll Calls
Yes: 214 • No: 52
Sponsored By: Byron Pelton (Republican), Dusty Johnson (Republican), Dylan Roberts (Democratic), Kyle Brown (Democratic)
Signed by Governor
Personalized for You
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
4 provisions identified: 2 benefits, 0 costs, 2 mixed.
Beginning January 1, 2027, pharmacy benefit managers cannot favor a brand-name drug over an equivalent generic or biosimilar. A brand-name drug can be preferred only when its net acquisition cost is lower and consumers pay less out of pocket. Managers can negotiate limits on wholesale acquisition cost increases for drugs on their covered-drug lists and in benefit designs. They can still negotiate rebates or discounts as a share of list price. The law does not require price-limit agreements or set a household savings amount.
Health plan contracts must require pharmacy benefit managers to provide drug-cost reports, including claim details and prohibited income subject to pass-through. Reports are free and due within 30 days after plan notice, or at agreed regular intervals needed to check compliance. Contracts must allow annual compliance audits, and Colorado’s Insurance Commissioner can issue enforcement rules. The law applies to conduct beginning January 1, 2027. A referendum petition filed within 90 days after final adjournment suspends challenged provisions pending approval at the November 2026 general election; approved provisions start January 1, 2027, or the governor’s official vote declaration date, whichever is later.
Beginning January 1, 2027, Colorado allows pharmacy benefit managers (PBMs) to earn a single flat-dollar service fee for providing a prescription drug. Written health plan agreements must clearly state the fee, which can vary by client size, services, value-based payments, and other factors. Health plans, including self-funded plans, must pay PBMs for reducing total drug spending over a defined period and for direct services. PBMs cannot earn income tied to a drug’s net acquisition cost through markups, copayments above drug cost, spread pricing, purchasing-group revenue, manufacturer revenue, or other pricing arrangements. Insurance-carrier-linked PBMs must pass accidentally collected prohibited income to plan members.
Beginning January 1, 2027, pharmacy benefit managers must pay pharmacies using a national drug-cost benchmark. Payment equals the National Average Drug Acquisition Cost for drug ingredients, plus a reasonable and adequate dispensing fee. If that benchmark is unavailable when the drug is dispensed, payment must be at least the Wholesale Acquisition Cost. The rule covers independent pharmacies and manager-affiliated retail, mail-order, and specialty pharmacies. It does not set what consumers pay.
Byron Pelton
Republican • Senate
Dusty Johnson
Republican • House
Dylan Roberts
Democratic • Senate
Kyle Brown
Democratic • House
Andrew Boesenecker
Democratic • House
Amy Paschal
Democratic • House
Alex Valdez
Democratic • House
Emily Sirota
Democratic • House
Elizabeth Velasco
Democratic • House
Jennifer Bacon
Democratic • House
Junie Joseph
Democratic • House
Julie McCluskie
Democratic • House
Karen McCormick
Democratic • House
Katie Stewart
Democratic • House
Lesley Smith
Democratic • House
Monica Duran
Democratic • House
Mandy Lindsay
Democratic • House
Regina English
Democratic • House
Rep. S. Bird
Affiliation unavailable
Sheila Lieder
Democratic • House
Steven Woodrow
Democratic • House
Yara Zokaie
Democratic • House
Cathy Kipp
Democratic • Senate
Iman Jodeh
Democratic • Senate
Judy Amabile
Democratic • Senate
Jeff Bridges
Democratic • Senate
Katie Wallace
Democratic • Senate
Mike Weissman
Democratic • Senate
Nick Hinrichsen
Democratic • Senate
Tony Exum
Democratic • Senate
All Roll Calls
Yes: 214 • No: 52
House vote • 5/7/2025
Senate amendments: Repass
Yes: 49 • No: 16
House vote • 5/7/2025
Senate amendments: Concur
Yes: 56 • No: 8
Senate vote • 5/6/2025
Third reading: Bill
Yes: 29 • No: 6
Senate vote • 4/30/2025
Refer House Bill 25-1094 to the Committee of the Whole.
Yes: 7 • No: 0
Senate vote • 4/24/2025
Refer House Bill 25-1094, as amended, to the Committee on Appropriations.
Yes: 7 • No: 2
House vote • 3/17/2025
Third reading: Bill
Yes: 48 • No: 15
House vote • 3/7/2025
Refer House Bill 25-1094 to the Committee of the Whole.
Yes: 8 • No: 2
House vote • 2/19/2025
Refer House Bill 25-1094, as amended, to the Committee on Appropriations.
Yes: 10 • No: 3
Governor Signed
Signed by the Speaker of the House
Signed by the President of the Senate
Sent to the Governor
House Considered Senate Amendments - Result was to Concur - Repass
Senate Third Reading Passed - No Amendments
House Considered Senate Amendments - Result was to Laid Over Daily
Senate Third Reading Laid Over Daily - No Amendments
Senate Second Reading Special Order - Passed with Amendments - Committee
Senate Committee on Appropriations Refer Unamended to Senate Committee of the Whole
Senate Committee on Health & Human Services Refer Amended to Appropriations
Introduced In Senate - Assigned to Health & Human Services
House Third Reading Passed - No Amendments
House Second Reading Special Order - Passed with Amendments - Committee, Floor
House Second Reading Laid Over Daily - No Amendments
House Committee on Appropriations Refer Unamended to House Committee of the Whole
House Committee on Health & Human Services Refer Amended to Appropriations
Introduced In House - Assigned to Health & Human Services
Engrossed
Final Act
Introduced
Reengrossed
Rerevised
Revised
Signed Act
HB25-1108, Prohibitions in Rental Agreements Due to Death
HB25-1043, Owner Equity Protection in Homeowners' Association Foreclosure Sales
HB25-1031, Law Enforcement Whistleblower Protection
HB25-1021, Tax Incentives for Employee-Owned Businesses
HB25-1080, Wireless Telephone Infrastructure Deployment Incentives
HB25-1001, Enforcement Wage Hour Laws